Her-2 targeted therapy: Beyond breast cancer and trastuzumab |
| |
Authors: | Keith T Flaherty MD Marcia S Brose MD PhD |
| |
Institution: | (1) Abramson Cancer Center of the University of Pennsylvania, 51 N. 39th Street, MAB 103, 19104 Philadelphia, PA, USA |
| |
Abstract: | Her-2 is a validated therapeutic target in breast cancer. The two critical questions that remain regarding Her-2 targeting
concern 1) the relevance of Her-2 inhibition in other malignancies and 2) the ability of novel agents to achieve greater Her-2
inhibition than trastuzumab. The contribution of cell signaling effects and immunologic mechanisms to the effect of trastuzumab
in vivo remains poorly understood. Thus, the preclinical data that support the greater efficacy of novel Her-2 antibodies
or small molecule tyrosine kinase inhibitors remain to be validated in clinical trials. In this review, we discuss the evidence
from recent trastuzumab clinical trials as a point of departure for consideration of novel Her-2 targeted therapies. Preliminary
results from early clinical trials suggest that Her-2 tyrosine kinase inhibitors may extend the population for which this
strategy offers therapeutic effect. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|